Tag: romosozumab
Amgen, UCB resubmit BLA of EVENITY osteoporosis drug to FDA
Amgen and UCB have resubmitted the biologics license application (BLA) of their investigational osteoporosis drug EVENITY (romosozumab) to the US Food and Drug Administration (FDA) ... Read More